Infant Formula
11
3
4
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
Reason for Prescribing Rice Infant Formula
Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants
Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants
Effects of Breast Milk Simulated Infant Formula
The Role of Human Milk Oligosaccharides and Microbiomes on Infantile Colic and Atopic Dermatitis in Term Infants
Gastric Layering and Monitoring II
Growth, Allergy and Neurodevelopment in Infants on Hydrolysed Formula
Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease
Gastrointestinal Tolerability of a Partially Hydrolyzed Ready-to-feed Infant Formula in Healthy Newborns
Study of Infant Diets on Estrogen Activity and Development
Supplementation of Infant Formula With Synbiotics